A Numerical Method for Analysis of In Vitro Time-Dependent Inhibition Data. Part 1. Theoretical Considerations

Inhibition of cytochromes P450 by time-dependent inhibitors (TDI) is a major cause of clinical drug-drug interactions. It is often difficult to predict in vivo drug interactions based on in vitro TDI data. In part 1 of these manuscripts, we describe a numerical method that can directly estimate TDI parameters for a number of kinetic schemes. Datasets were simulated for Michaelis-Menten (MM) and several atypical kinetic schemes. Ordinary differential equations were solved directly to parameterize kinetic constants. For MM kinetics, much better estimates of KI can be obtained with the numerical method, and even IC50 shift data can provide meaningful estimates of TDI kinetic parameters. The standard replot method can be modified to fit non-MM data, but normal experimental error precludes this approach. Non-MM kinetic schemes can be easily incorporated into the numerical method, and the numerical method consistently predicts the correct model at errors of 10% or less. Quasi-irreversible inactivation and partial inactivation can be modeled easily with the numerical method. The utility of the numerical method for the analyses of experimental TDI data is provided in our companion manuscript in this issue of Drug Metabolism and Disposition (Korzekwa et al., 2014b).

[1]  B. Faller,et al.  CYP3A Time-Dependent Inhibition Risk Assessment Validated with 400 Reference Drugs , 2011, Drug Metabolism and Disposition.

[2]  R. Obach,et al.  Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug–drug interaction risk assessment , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[3]  K. Koeplinger,et al.  Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A. , 1998, The Journal of pharmacology and experimental therapeutics.

[4]  M. Mohutsky,et al.  Irreversible enzyme inhibition kinetics and drug-drug interactions. , 2014, Methods in molecular biology.

[5]  J. Crowley,et al.  Mechanism-based inactivation of rat liver cytochrome P4502B1 by phencyclidine and its oxidative product, the iminium ion. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[6]  A. Galetin,et al.  Progress Curve Mechanistic Modeling Approach for Assessing Time-Dependent Inhibition of CYP3A4 , 2012, Drug Metabolism and Disposition.

[7]  Shiew-Mei Huang,et al.  Predicting Drug–Drug Interactions: An FDA Perspective , 2009, The AAPS Journal.

[8]  T. Poulos,et al.  Crystallization of cytochromes P450 and substrate-enzyme interactions. , 2004, Current topics in medicinal chemistry.

[9]  L. Wienkers,et al.  Mechanism-Based Inactivation of Cytochrome P450 3A4 by Mibefradil through Heme Destruction , 2011, Drug Metabolism and Disposition.

[10]  M. Huang,et al.  Studies on the mechanism of activation of microsomal benzo[a]pyrene hydroxylation by flavonoids. , 1981, The Journal of biological chemistry.

[11]  B. Metcalf,et al.  Catalytic inhibition of γ-aminobutyric acid-α-ketoglutarate transaminase of bacterial origin by 4-aminohex-5-ynoic acid, a substrate analog , 1975 .

[12]  F. Guengerich,et al.  Cooperativity in oxidations catalyzed by cytochrome P450 3A4. , 1997, Biochemistry.

[13]  B. Ma,et al.  Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[14]  W. Atkins,et al.  Non-Michaelis-Menten kinetics in cytochrome P450-catalyzed reactions. , 2005, Annual review of pharmacology and toxicology.

[15]  S. Hall,et al.  Mechanism-Based Inhibition of Human Cytochromes P450: In Vitro Kinetics and In Vitro—In Vivo Correlations , 2001 .

[16]  O. Hankinson,et al.  The Mibefradil Derivative NNC55-0396, a Specific T-Type Calcium Channel Antagonist, Exhibits Less CYP3A4 Inhibition than Mibefradil , 2008, Drug Metabolism and Disposition.

[17]  G. Tucker,et al.  MECHANISM-BASED INACTIVATION OF CYP2D6 BY METHYLENEDIOXYMETHAMPHETAMINE , 2004, Drug Metabolism and Disposition.

[18]  G. Tucker,et al.  MECHANISM-BASED INACTIVATION OF CYP2D6 BY METHYLENEDIOXYMETHAMPHETAMINE , 2004, Drug Metabolism and Disposition.

[19]  K. Korzekwa,et al.  Enzyme kinetics of oxidative metabolism: cytochromes P450. , 2014, Methods in molecular biology.

[20]  A. Conney,et al.  In vivo activation of zoxazolamine metabolism by flavone. , 1982, Science.

[21]  Namandjé N. Bumpus,et al.  Mechanism-based inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications. , 2008, Chemical research in toxicology.

[22]  G. Bellward,et al.  Effect of cimetidine on hepatic cytochrome P450: evidence for formation of a metabolite-intermediate complex. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[23]  H. Kotaki,et al.  Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[24]  Stephen Fowler,et al.  In Vitro Evaluation of Reversible and Irreversible Cytochrome P450 Inhibition: Current Status on Methodologies and their Utility for Predicting Drug–Drug Interactions , 2008, The AAPS Journal.

[25]  R. Silverman Mechanism-based enzyme inactivators. , 1995, Methods in enzymology.

[26]  Chuang Lu,et al.  The Conduct of in Vitro Studies to Address Time-Dependent Inhibition of Drug-Metabolizing Enzymes: A Perspective of the Pharmaceutical Research and Manufacturers of America , 2009, Drug Metabolism and Disposition.

[27]  S. G. Waley,et al.  Kinetics of suicide substrates. , 1980, The Biochemical journal.

[28]  K. Korzekwa,et al.  Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. , 1994, Biochemistry.

[29]  A. Rettie,et al.  Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. , 1998, Biochemistry.

[30]  D. Jones,et al.  Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. , 1999, The Journal of pharmacology and experimental therapeutics.

[31]  D. Tweedie,et al.  A Numerical Method for Analysis of In Vitro Time-Dependent Inhibition Data. Part 2. Application to Experimental Data , 2014, Drug Metabolism and Disposition.

[32]  R. Kitz,et al.  Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. , 1962, The Journal of biological chemistry.

[33]  C. Ernest,et al.  Mechanism-Based Inactivation of CYP3A by HIV Protease Inhibitors , 2005, Journal of Pharmacology and Experimental Therapeutics.

[34]  Y. Sugiyama,et al.  Prediction of In Vivo Interaction Between Triazolam and Erythromycin Based on In Vitro Studies Using Human Liver Microsomes and Recombinant Human CYP3A4 , 2000, Pharmaceutical Research.

[35]  P. Watkins,et al.  THE HUMAN CYP3A SUBFAMILY: PRACTICAL CONSIDERATIONS* , 2000, Drug metabolism reviews.

[36]  S. Waley Kinetics of suicide substrates. Practical procedures for determining parameters. , 1985, The Biochemical journal.

[37]  Nina Isoherranen,et al.  Surface plasmon resonance analysis of antifungal azoles binding to CYP3A4 with kinetic resolution of multiple binding orientations. , 2006, Biochemistry.

[38]  Fabio Garofolo,et al.  Bioanalytical Method Validation , 2004 .

[39]  K. He,et al.  Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. , 1998, Chemical research in toxicology.

[40]  M. Correia,et al.  Inhibition of Cytochrome P450 Enzymes , 2015 .

[41]  Karthik Venkatakrishnan,et al.  Mechanism-Based Inactivation of Human Cytochrome P450 Enzymes and the Prediction of Drug-Drug Interactions , 2007, Drug Metabolism and Disposition.

[42]  R. Sheridan,et al.  Inhibition of recombinant cytochrome P450 isoforms 2D6 and 2C9 by diverse drug-like molecules. , 2007, Journal of medicinal chemistry.